Previous 10 | Next 10 |
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Vigabatrin Powder for Oral Solution, USP in 500 mg per packet, a therapeutic equivalent generic ver...
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that it has launched Versavo ® (bevacizumab), a biosimilar of Roche’s Avastin ® in India, indicated for the treatment of several types of cancers (metastatic colorectal cancer, non-s...
U.S. Senator Bernie Sanders (I-VT) and Representative Elijah Cummings (D-MD - 7th district) have launched an investigation targeting Teva Pharmaceutical Industries ( TEVA -8% ), Mylan N.V. ( MYL -7.8% ) and Heritage Pharmaceuticals for allegedly obstructing a Congressional inquiry into...
– Companies will partner to advance small molecules in up to six discrete projects, including three existing programs against specific predetermined targets – Exelixis, Inc. (Nasdaq: EXEL) today announced that it has entered into an exclusive collaboration, option and l...
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Pregabalin Capsules a therapeutic equivalent generic version of Lyrica ® (pregabalin) Capsule...
The following slide deck was published by Dr. Reddy's Laboratories Limited in conjunction with their 2020 Q1 earnings Read more ...
Dr. Reddy's ( RDY -3.8% ) Q1 results : Revenues: $558M (+3.3%). More news on: Dr. Reddy's Laboratories Limited, Healthcare stocks news, Earnings news and commentary, Read more ...
Dr. Reddy’s Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY) today announced its consolidated financial results for the quarter ended June 30, 2019 under International Financial Reporting Standards (IFRS). Commenting on the results, CEO and Co-chairman, GV Prasad said ...
Dr. Reddy's (NYSE: RDY ): Q1 GAAP EPS of $0.58. More news on: Dr. Reddy's Laboratories Limited, Earnings news and commentary, Healthcare stocks news, Read more ...
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Ramelteon Tablets, 8 mg, a therapeutically equivalent generic version of Rozerem ® (ramelteon...
News, Short Squeeze, Breakout and More Instantly...
Dr. Reddy's Laboratories Ltd Company Name:
RDY Stock Symbol:
NYSE Market:
Dr. Reddy's Laboratories Ltd Website:
2024-07-04 03:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Portfolio to be acquired consists of global NRT brand Nicotinell and its local market-leading brand names Nicabate, Habitrol and Thrive in markets outside of the United States Acquisition seen as ideal anchor to continue to build the company’s global consumer healthcare OTC busines...
Aurigene Pharmaceutical Services Limited (“Aurigene”), a Dr. Reddy’s Laboratories Limited company, inaugurated its biologics facility spread across 70,000 sq.ft. in Genome Valley, a bio cluster, located in Hyderabad, India. The facility is designed to serve customers with pro...